Attruby (Acoramidis HCl) Patent Expiration, LOE Window & CMS Spending

Attruby (Acoramidis HCl) by BridgeBio Pharma: FDA Orange Book core substance LOE 2038-02-16 (last listed 2039-08-16), 0 AB generics, $870K 2024 CMS Part D & Medicaid spend, and $18,759 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBridgeBio Pharma
FDA Application & PathwayN216540 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-02-16
Last Listed Patent or Exclusivity Date2039-08-16
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$870K
2024 Medicare Part D Spend$870K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($18,759 intro WAC)